News

Orion Corporation Expands ADC Development with Glykos Partnership

Orion Corporation Expands ADC Development with Glykos Partnership

Orion Corporation and Glykos Enhance Their Collaboration

Orion Corporation and Glykos Finland Oy have recently announced the extension of their promising research collaboration and licensing agreement aimed at developing next-generation antibody-drug conjugates (ADCs). This strategic partnership signifies both companies' commitment to leveraging advanced technologies to create innovative cancer therapies.

Details of the Extended Agreement

The new agreement allows Orion to access Glykos’ state-of-the-art ADC technologies, paving the way for potential development in three additional programs. This is alongside the three ADC projects detailed in their previous agreement. Orion will manage aspects such as target selection, research, development, and the commercialization of these novel ADCs, focusing primarily on solid tumors.

Financial Framework and Benefits

The financial structure of the extended agreement mirrors that of the initial contract, ensuring a consistent foundation for both parties. Glykos will receive milestone payments during the ADCs' development phases and will also benefit from royalties from product sales once the ADCs enter the market. This setup highlights the innovative approach both companies are taking to foster a win-win scenario in the oncology space.

Insights from Leadership

Professor Outi Vaarala, Executive Vice President at Orion, emphasized the importance of this collaboration in enhancing therapeutic options available for cancer patients. He stated, "This successful collaboration allows us to continue leveraging [Glykos'] advanced ADC technology and underscores our commitment to developing new treatment options for cancer patients."

Glykos' Perspective on Expansion

Juhani Saarinen, the CEO of Glykos, expressed enthusiasm about the extension of the partnership, noting that it highlights the potential of their ADC technology. He remarked, "We are excited to expand our collaboration with Orion, whose expertise in cancer therapies is crucial for bringing effective treatments to cancer patients." This sentiment speaks volumes about the collaborative spirit shared between the two organizations.

Background on Orion Corporation

Orion Corporation boasts over a hundred years of experience in the pharmaceutical industry. Based in the Nordic region, the company is dedicated to improving global health through its comprehensive range of human and veterinary pharmaceuticals, active pharmaceutical ingredients, and consumer health products. Orion's primary areas of research and development focus on oncology and pain management, with various proprietary products designed to address cancer, neurological diseases, and respiratory ailments.

About Glykos and Its ADC Innovations

Glykos specializes in groundbreaking ADC technologies and is committed to transforming cancer treatment. Their proprietary hydrophilic payload and linker technology address existing limitations in ADC effectiveness, ensuring enhanced efficacy, tolerability, pharmacokinetics, and versatile conjugation with monoclonal antibodies. Glykos' mission is to expand the therapeutic index, ultimately aiming to prolong survival and improve the quality of life for cancer patients.

Contact Information and More

For inquiries related to this partnership or other matters, Orion Corporation can be reached through its Vice President of External Science and Partnering, Antti Haapalinna, at +358 50 966 7670 or via email at antti.haapalinna@orionpharma.com.

Frequently Asked Questions

What is the primary focus of the Orion and Glykos collaboration?

The focus is on developing next-generation antibody-drug conjugates (ADCs) for cancer treatment.

How many additional ADC projects are included in the new agreement?

The new agreement allows for the development of three additional ADC programs alongside the original three.

What are the financial terms of the extended agreement?

The financial terms remain consistent with the original agreement, including milestone payments and royalties for Glykos.

Who are the key executives involved in this collaboration?

Key figures include Professor Outi Vaarala from Orion and Juhani Saarinen from Glykos, both supporting the strategic directions of their respective companies.

What technological advancements does Glykos bring to the partnership?

Glykos offers advanced ADC technology focusing on hydrophilic payloads and linker technologies to enhance treatment efficacy and tolerability in cancer therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 9

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 84

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 89

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 119

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 156

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 179

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 132

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading

Top 5 Most Recently Viewed Articles

Social Media Buzz Powers Hainan's Travel Boom

Updated Category News Views 205

Social Media Buzz Powers Hainan's Travel Boom This year marks a remarkable shift in Hainan's tourism, driven by the advent of visa-free travel access for international visitors. As the beautiful island in southern China opens its doors wider, a surge in travelers, especially travel bloggers from around the globe, is noticeable. Influencers from diverse backgrounds,...

Continue Reading
Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates

Updated Category News Views 375

Kodiak Sciences Reports Q3 2025 Financial Milestones and Updates Kodiak Sciences Inc. (Nasdaq: KOD) has recently shared significant business highlights along with financial results for the third quarter of 2025. This biotechnology company is making strides in the field of retinal medicine. 'We are witnessing a period marked by sustained momentum,' expressed Victor...

Continue Reading
Vaisala Initiates Share Repurchase Program to Enhance Incentives

Updated Category News Views 193

Vaisala’s Strategy for Share Repurchases Vaisala Corporation is embarking on an important journey to repurchase its own shares as part of a broader incentive plan. This strategic decision follows the authorization granted by the Annual General Meeting, reflecting the company's commitment to fostering a rewarding environment for its employees. As a key player in climate...

Continue Reading
Investigating Customer Bancorp, Inc. Losses: Understand Your Rights

Updated Category News Views 92

Exploring Customers Bancorp, Inc.'s Recent Challenges Customers Bancorp, Inc., identified by the ticker CUBI, is dealing with significant accusations regarding the truthfulness of the business information it has shared with the public. The Rosen Law Firm, a respected advocate for investor rights, is currently looking into securities claims tied to these allegations. If...

Continue Reading
Allurity and Onevinn: Transforming Cybersecurity Together

Updated Category News Views 374

Allurity Expands its Cybersecurity Portfolio with Onevinn Acquisition Allurity, a prominent European provider of cybersecurity services, has exciting news to share. The company has taken a significant step forward by acquiring Onevinn, a Swedish company renowned for its intelligent security and managed services. This move not only showcases Allurity's ambitions but also...

Continue Reading